AVR 02

Drug Profile

AVR 02

Alternative Names: AVR-02

Latest Information Update: 09 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AVROBIO
  • Class Gene therapies
  • Mechanism of Action Alpha-galactosidase replacements; Enzyme replacements; Gene modulators; Immunogenetic stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Fabry's disease

Most Recent Events

  • 02 Aug 2016 Phase-I clinical trials in Fabry's disease in USA (IV)
  • 18 Feb 2016 AVROBIO in-licenses innovative cell and gene therapy technologies from University Health Network
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top